41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients

Robert L. Fitzgerald, Darren J. Hillegonds, Douglas W. Burton, Terrance L. Griffin, Scott Mullaney, John S. Vogel, Leonard J. Deftos, David A. Herold

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Monitoring bone resorption with measurements of bone density and biochemical markers is indirect. We hypothesized that bone resorption can be studied directly by serial measurements of the ratio 41Ca/Ca in serum after in vivo labeling of calcium pools with 41Ca. We report the preparation of an intravenous 41Ca dose suitable for humans, an analytical method for determining 41Ca/Ca isotope ratios in biological samples, and studies in human volunteers. Methods: 41Ca was formulated and aliquoted into individual vials, and to the extent possible, the 41Ca doses were tested according to US Pharmacopeia (USP) guidelines. A 10 nCi dose of 41Ca was administered intravenously to 4 end stage renal disease (ESRD) patients on hemodialysis and 4 healthy control individuals. Distribution kinetics were determined over 168 days. Calcium was isolated with 3 precipitation steps and a cation-exchange column, and 41Ca/Ca ratios in serum were then measured by accelerator mass spectrometry. Results: The dosing solution was chemically and radiologically pure, contained <0.1 endotoxin Unit/mL, and passed USP sterility tests. Quantification of 41Ca/Ca ratios was linear from 6 × 10 -14 to 9.1 × 10-10. The run-to-run imprecision (as CV) of the method was 4% at 4.6 × 10-11 and 6% at 9.1 × 10-10. The area under the curve of 41Ca in the central compartment vs time was significantly less for ESRD patients than for controls (P <0.005). Conclusions: Isotope ratios spanning 5 orders of magnitude can be measured by accelerator mass spectrometry with excellent precision in the range observed in samples collected from patients who have received 10 nCi of 41Ca. The 41Ca at this dose caused no adverse effects in 8 volunteers. This is the first report of the use of 41Ca to monitor differences in bone turnover between healthy individuals and ESRD patients.

Original languageEnglish (US)
Pages (from-to)2095-2102
Number of pages8
JournalClinical Chemistry
Volume51
Issue number11
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Metabolism
Chronic Kidney Failure
Particle accelerators
Mass spectrometry
Mass Spectrometry
Bone
Calcium
Pharmacopoeias
Bone Resorption
Isotopes
Volunteers
Bone Remodeling
Serum
Endotoxins
Bone Density
Labeling
Infertility
Area Under Curve
Renal Dialysis
Cations

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Fitzgerald, R. L., Hillegonds, D. J., Burton, D. W., Griffin, T. L., Mullaney, S., Vogel, J. S., ... Herold, D. A. (2005). 41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients. Clinical Chemistry, 51(11), 2095-2102. https://doi.org/10.1373/clinchem.2005.049650

41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients. / Fitzgerald, Robert L.; Hillegonds, Darren J.; Burton, Douglas W.; Griffin, Terrance L.; Mullaney, Scott; Vogel, John S.; Deftos, Leonard J.; Herold, David A.

In: Clinical Chemistry, Vol. 51, No. 11, 11.2005, p. 2095-2102.

Research output: Contribution to journalArticle

Fitzgerald, RL, Hillegonds, DJ, Burton, DW, Griffin, TL, Mullaney, S, Vogel, JS, Deftos, LJ & Herold, DA 2005, '41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients', Clinical Chemistry, vol. 51, no. 11, pp. 2095-2102. https://doi.org/10.1373/clinchem.2005.049650
Fitzgerald RL, Hillegonds DJ, Burton DW, Griffin TL, Mullaney S, Vogel JS et al. 41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients. Clinical Chemistry. 2005 Nov;51(11):2095-2102. https://doi.org/10.1373/clinchem.2005.049650
Fitzgerald, Robert L. ; Hillegonds, Darren J. ; Burton, Douglas W. ; Griffin, Terrance L. ; Mullaney, Scott ; Vogel, John S. ; Deftos, Leonard J. ; Herold, David A. / 41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients. In: Clinical Chemistry. 2005 ; Vol. 51, No. 11. pp. 2095-2102.
@article{75d9c84827474c1d8234730f6add06b9,
title = "41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients",
abstract = "Background: Monitoring bone resorption with measurements of bone density and biochemical markers is indirect. We hypothesized that bone resorption can be studied directly by serial measurements of the ratio 41Ca/Ca in serum after in vivo labeling of calcium pools with 41Ca. We report the preparation of an intravenous 41Ca dose suitable for humans, an analytical method for determining 41Ca/Ca isotope ratios in biological samples, and studies in human volunteers. Methods: 41Ca was formulated and aliquoted into individual vials, and to the extent possible, the 41Ca doses were tested according to US Pharmacopeia (USP) guidelines. A 10 nCi dose of 41Ca was administered intravenously to 4 end stage renal disease (ESRD) patients on hemodialysis and 4 healthy control individuals. Distribution kinetics were determined over 168 days. Calcium was isolated with 3 precipitation steps and a cation-exchange column, and 41Ca/Ca ratios in serum were then measured by accelerator mass spectrometry. Results: The dosing solution was chemically and radiologically pure, contained <0.1 endotoxin Unit/mL, and passed USP sterility tests. Quantification of 41Ca/Ca ratios was linear from 6 × 10 -14 to 9.1 × 10-10. The run-to-run imprecision (as CV) of the method was 4{\%} at 4.6 × 10-11 and 6{\%} at 9.1 × 10-10. The area under the curve of 41Ca in the central compartment vs time was significantly less for ESRD patients than for controls (P <0.005). Conclusions: Isotope ratios spanning 5 orders of magnitude can be measured by accelerator mass spectrometry with excellent precision in the range observed in samples collected from patients who have received 10 nCi of 41Ca. The 41Ca at this dose caused no adverse effects in 8 volunteers. This is the first report of the use of 41Ca to monitor differences in bone turnover between healthy individuals and ESRD patients.",
author = "Fitzgerald, {Robert L.} and Hillegonds, {Darren J.} and Burton, {Douglas W.} and Griffin, {Terrance L.} and Scott Mullaney and Vogel, {John S.} and Deftos, {Leonard J.} and Herold, {David A.}",
year = "2005",
month = "11",
doi = "10.1373/clinchem.2005.049650",
language = "English (US)",
volume = "51",
pages = "2095--2102",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - 41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients

AU - Fitzgerald, Robert L.

AU - Hillegonds, Darren J.

AU - Burton, Douglas W.

AU - Griffin, Terrance L.

AU - Mullaney, Scott

AU - Vogel, John S.

AU - Deftos, Leonard J.

AU - Herold, David A.

PY - 2005/11

Y1 - 2005/11

N2 - Background: Monitoring bone resorption with measurements of bone density and biochemical markers is indirect. We hypothesized that bone resorption can be studied directly by serial measurements of the ratio 41Ca/Ca in serum after in vivo labeling of calcium pools with 41Ca. We report the preparation of an intravenous 41Ca dose suitable for humans, an analytical method for determining 41Ca/Ca isotope ratios in biological samples, and studies in human volunteers. Methods: 41Ca was formulated and aliquoted into individual vials, and to the extent possible, the 41Ca doses were tested according to US Pharmacopeia (USP) guidelines. A 10 nCi dose of 41Ca was administered intravenously to 4 end stage renal disease (ESRD) patients on hemodialysis and 4 healthy control individuals. Distribution kinetics were determined over 168 days. Calcium was isolated with 3 precipitation steps and a cation-exchange column, and 41Ca/Ca ratios in serum were then measured by accelerator mass spectrometry. Results: The dosing solution was chemically and radiologically pure, contained <0.1 endotoxin Unit/mL, and passed USP sterility tests. Quantification of 41Ca/Ca ratios was linear from 6 × 10 -14 to 9.1 × 10-10. The run-to-run imprecision (as CV) of the method was 4% at 4.6 × 10-11 and 6% at 9.1 × 10-10. The area under the curve of 41Ca in the central compartment vs time was significantly less for ESRD patients than for controls (P <0.005). Conclusions: Isotope ratios spanning 5 orders of magnitude can be measured by accelerator mass spectrometry with excellent precision in the range observed in samples collected from patients who have received 10 nCi of 41Ca. The 41Ca at this dose caused no adverse effects in 8 volunteers. This is the first report of the use of 41Ca to monitor differences in bone turnover between healthy individuals and ESRD patients.

AB - Background: Monitoring bone resorption with measurements of bone density and biochemical markers is indirect. We hypothesized that bone resorption can be studied directly by serial measurements of the ratio 41Ca/Ca in serum after in vivo labeling of calcium pools with 41Ca. We report the preparation of an intravenous 41Ca dose suitable for humans, an analytical method for determining 41Ca/Ca isotope ratios in biological samples, and studies in human volunteers. Methods: 41Ca was formulated and aliquoted into individual vials, and to the extent possible, the 41Ca doses were tested according to US Pharmacopeia (USP) guidelines. A 10 nCi dose of 41Ca was administered intravenously to 4 end stage renal disease (ESRD) patients on hemodialysis and 4 healthy control individuals. Distribution kinetics were determined over 168 days. Calcium was isolated with 3 precipitation steps and a cation-exchange column, and 41Ca/Ca ratios in serum were then measured by accelerator mass spectrometry. Results: The dosing solution was chemically and radiologically pure, contained <0.1 endotoxin Unit/mL, and passed USP sterility tests. Quantification of 41Ca/Ca ratios was linear from 6 × 10 -14 to 9.1 × 10-10. The run-to-run imprecision (as CV) of the method was 4% at 4.6 × 10-11 and 6% at 9.1 × 10-10. The area under the curve of 41Ca in the central compartment vs time was significantly less for ESRD patients than for controls (P <0.005). Conclusions: Isotope ratios spanning 5 orders of magnitude can be measured by accelerator mass spectrometry with excellent precision in the range observed in samples collected from patients who have received 10 nCi of 41Ca. The 41Ca at this dose caused no adverse effects in 8 volunteers. This is the first report of the use of 41Ca to monitor differences in bone turnover between healthy individuals and ESRD patients.

UR - http://www.scopus.com/inward/record.url?scp=27444435999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444435999&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2005.049650

DO - 10.1373/clinchem.2005.049650

M3 - Article

C2 - 16141289

AN - SCOPUS:27444435999

VL - 51

SP - 2095

EP - 2102

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -